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Clinical Infectious Diseases
SUPPLEMENT ARTICLE

Illness Severity and Outcomes Among Enteric Fever Cases
From Bangladesh, Nepal, and Pakistan: Data From the
Surveillance for Enteric Fever in Asia Project, 2016–2019
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USA, 3Applied Epidemiology, Sabin Vaccine Institute, Washington, DC, USA, 4Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California, USA, 5Child Health Research
Foundation, Department of Microbiology, Dhaka Shishu Hospital, Dhaka, Bangladesh, 6Bangladesh Institute of Child Health, Dhaka Shishu Hospital, Sher-E-Bangla Nagar, Dhaka, Bangladesh,
7
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Background. Enteric fever can lead to prolonged hospital stays, clinical complications, and death. The Surveillance for Enteric
Fever in Asia Project (SEAP), a prospective surveillance study, characterized the burden of enteric fever, including illness severity, in
selected settings in Bangladesh, Nepal, and Pakistan. We assessed disease severity, including hospitalization, clinical complications,
and death among SEAP participants.
Methods. We analyzed clinical and laboratory data from blood culture–confirmed enteric fever cases enrolled in SEAP hospitals
and associated network laboratories from September 2016 to September 2019. We used hospitalization and duration of hospital stay
as proxies for severity. We conducted a follow-up interview 6 weeks after enrollment to ascertain final outcomes.
Results. Of the 8705 blood culture-confirmed enteric fever cases enrolled, we identified 6 deaths (case-fatality ratio, .07%; 95%
CI, .01–.13%), 2 from Nepal, 4 from Pakistan, and none from Bangladesh. Overall, 1.7% (90/5205) of patients recruited from SEAP
hospitals experienced a clinical complication (Bangladesh, 0.6% [18/3032]; Nepal, 2.3% [12/531]; Pakistan, 3.7% [60/1642]). The
most identified complications were hepatitis (n = 36), septic shock (n = 22), and pulmonary complications/pneumonia (n = 13).
Across countries, 32% (2804/8669) of patients with hospitalization data available were hospitalized (Bangladesh, 27% [1295/4868];
Nepal, 29% [455/1595]; Pakistan, 48% [1054/2206]), with a median hospital stay of 5 days (IQR, 3–7).
Conclusions. While defined clinical complications and deaths were uncommon at the SEAP sites, the high proportion of hospitalizations and prolonged hospital stays highlight illness severity and the need for enteric fever control measures, including the use
of typhoid conjugate vaccines.
Keywords. enteric fever; typhoid; severity; mortality; antimicrobial resistance.
Enteric fever (typhoid and paratyphoid fevers), caused by
Salmonella enterica serovars Typhi (S. Typhi) and Paratyphi
A, B, and C (S. Paratyphi), remains an important public health
problem in lower-income countries, especially in South Asia
and sub-Saharan Africa [1, 2]. Typhoid fever is estimated to
cause approximately 11 million illnesses and 116 800 deaths
globally, while paratyphoid fever is estimated to cause 3.4
million illnesses and 19 100 deaths [2]. S. Typhi is the most
common bloodstream infection in South Asia [3], the region
that accounts for almost 70% of the global enteric fever burden
and mortality [2].
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Before the widescale implementation of antibiotics, an estimated 10–15% of patients with enteric fever developed clinical
complications, the most severe including intestinal perforation,
gastrointestinal bleeding, and neurological complications [4].
Other complications such as hepatitis, pneumonia, myocarditis,
and cholecystitis are well described [5]; however, there is a paucity of recent data on the spectrum and frequency of clinical
complications [6, 7].
Additionally, determining the case fatality remains difficult
for several reasons [7]. Global disease burden and mortality estimations have typically relied on available data from multiple
sources; however, methodological differences, varying sample
sizes, and the use of different confirmatory tests limit the ability
to pool data across various studies. Existing reports of case fatality range from 0% to 23% depending on the geographic location and surveillance method used [6–9]. The most commonly
estimated case-fatality ratio is 1% [10], although estimates are
higher among those infected with multidrug-resistant strains
and differ among age groups and regions [4, 7–9, 11].
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METHODS
Study Setting

We conducted clinical and laboratory surveillance for enteric
fever from September 2016 to September 2019 at selected hospitals and through enhanced laboratory surveillance at additional participating hospitals and clinics (laboratory network
sites) that provide both outpatient and inpatient services.
SEAP sites in Dhaka, Bangladesh, included 2 large pediatric
hospitals and 3 laboratories (serving both adult and pediatric
populations); in Nepal, 1 hospital in Kathmandu and 1 in
Kavrepalanchok, plus 8 laboratories; and in Karachi, Pakistan,
2 tertiary hospitals, 3 laboratories, and surgical wards in 2 additional hospitals. Study site selection was described previously;
in brief, Bangladesh, Nepal, and Pakistan were selected as countries with a known burden of enteric fever. A review of health
facilities and laboratories led to the inclusion of several sites in
each country that had existing evidence of enteric fever burden,
the microbiological infrastructure to identify enteric fever by
blood culture, inpatient and outpatient facilities, and the ability
to obtain population-based sociodemographic data of the facility catchment area [14].

hospital stay were used as proxies for disease severity. We defined a hospitalization day as one that included an overnight
stay. Fluoroquinolone resistance included reduced susceptibility to ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin,
and gatifloxacin. Third-generation cephalosporin resistance included resistance to ceftriaxone, cefixime, cefotaxime,
cefpodoxime, and ceftazidime. Extensively drug-resistant
(XDR) S. Typhi is characterized as resistant to first-line antibiotics (chloramphenicol, ampicillin, and trimethoprimsulfamethoxazole), fluoroquinolones, and third-generation
cephalosporins [12].
Inclusion Criteria

We selected patients with blood culture–confirmed Typhi or
Paratyphi A of any age who (1) presented to outpatient departments, were identified in inpatient/surgical wards, or identified through hospital laboratories at SEAP hospitals or (2) were
identified at laboratory network sites. Inclusion criteria by enrollment location are described in Table 1.
Data Collection

Study teams reviewed the medical charts of all participants
from SEAP hospitals at the time of the enrollment visit and collected data on patient age, medications prescribed, duration of
hospital admission for those hospitalized, complications, and
clinical outcomes. Medical charts from laboratory network patients were not available for review. To ascertain final patient
outcomes (eg, resolved, died), study teams attempted to contact all patients with blood culture–confirmed enteric fever enrolled in the study by telephone by calling up to 5 times over
a 2-week period beginning 6 weeks following enrollment. The
study teams also collected phone numbers of family members
to contact if the patient could not be reached directly. If a patient sought medical care related to his or her illness during the
6 weeks between enrollment and follow-up, study teams attempted to obtain medical records from those visits to perform
chart reviews.

Definitions

Complications were defined as a diagnosis of a comorbid
condition confirmed by the treating physician as a complication of enteric fever. Hospital admission and duration of

Table 1.

Statistical Analysis

We calculated frequencies of complications and outcomes.
We conducted bivariate comparisons using Pearson’s

Inclusion Criteria by Enrollment Location for the Surveillance for Enteric Fever in Asia Project (SEAP)

Enrollment Location

Inclusion Criteria

Outpatient department

A patient presenting to the outpatient department (including emergency department) with a self-reported history of fever
for ≥3 consecutive days within the last 7 days and living within the defined catchment area

Inpatient department

A patient admitted to the hospital with a clinical suspicion or a confirmed diagnosis of enteric fever at any time during
hospitalization

Hospital laboratory

A patient with blood culture–confirmed Salmonella Typhi or Paratyphi A

Surgical department

A patient with a nontraumatic ileal perforation, even in the absence of laboratory confirmation, with no other known etiology

Laboratory network sites

A patient with blood culture–confirmed Salmonella Typhi or Paratyphi A
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Downloaded from https://academic.oup.com/cid/article/71/Supplement_3/S222/6013556 by guest on 26 January 2021

Recent data suggest a decline in enteric fever mortality, likely
due to improvements in clinical capacity and access to effective
treatments in endemic countries [8]. Updated mortality estimates, rates of complications, and severity data are necessary
to understand the burden of severe typhoid and inform health
policy, especially with growing antimicrobial resistance [7, 12].
The Surveillance for Enteric Fever in Asia Project (SEAP), a
multicountry, prospective, population-based surveillance project, was established to characterize the burden of enteric fever
in Bangladesh, Nepal, and Pakistan [13]. Here, we describe illness severity, including hospitalization, duration of hospital
stays, clinical complications, and deaths, among blood culture–
confirmed enteric fever cases over 36 months of surveillance in
the SEAP study.

Ethical Considerations

Informed consent was obtained from all participants or parents/
guardians of participants, as well as verbal assent from participants aged 11–17 years old. The study protocol was approved
by the Bangladesh Institute of Child Health Ethical Review
Committee, Nepal Health Research Council Ethical Review
Board, Pakistan Ethical Review Committee, and Stanford
Table 2.

University Institutional Review Board. This project was approved by the Centers for Disease Control and Prevention
(CDC) human subjects review as research with CDC not directly engaged, so a full institutional review board approval was
not required.
RESULTS

A total of 34 748 patients were enrolled from SEAP sites in
Bangladesh, Nepal, and Pakistan, of whom 8705 (25%) were
blood culture–confirmed for enteric fever; 5215 (60%) cases
were identified from the SEAP hospitals and 3490 (40%) cases
were identified through laboratory network sites. Of the confirmed cases, 7591 (87%) were positive for S. Typhi and 1114
(13%) were positive for S. Paratyphi A (Table 2). There was no
laboratory evidence of bacterial coinfection among the blood
culture–confirmed cases.
Clinical Complications

Over 99% (5205/5215) of the patients identified from SEAP
hospitals had medical records available for review, of whom
90 of 5205 (1.7%) experienced at least 1 complication during
the enrollment visit (Bangladesh, 0.6 % [18/3032]; Nepal, 2.3%
[12/531]; Pakistan, 3.7% [60/1642]). Seventeen (19%) patients
developed more than 1 complication. Complications included
hepatitis (n = 36), septic shock (n = 22), pulmonary complications/pneumonia (n = 13), encephalopathy (n = 12), intestinal
perforation (n = 10), gastrointestinal bleeding (n = 9), intestinal

Characteristics of Patients Enrolled in the Surveillance for Enteric Fever in Asia Project (SEAP)—Bangladesh, Nepal, and Pakistan, 2016–2019
Bangladesh

Patients enrolled, n

17 441

Nepal

Pakistan

7215

10 092

Total
34 748

Blood culture–confirmed enteric fevera cases, n (%)

4873 (28)

1602 (22)

2230 (22)

Patients identified from SEAP hospitals,b n (%)

3032 (62)

534 (33)

1649 (74)

5215 (60)

S. Typhi, n (% of culture-confirmed cases)

4131 (85)

1367 (85)

2093 (94)

7591 (87)

Age in years, median (IQR)
Male gender, n (%)
Days from fever onset to hospital presentation, median (IQR)

6 (3–14)
2754 (57)
5 (3–6)

Antibiotic use prior to enrollment visit, n (%)

1651 (34)

Hospitalization data available, n (%)

4868 (>99)

   Hospitalized, n (%)
   Age in years, median (IQR)
   Male gender, n (%)
   Days from fever onset to hospital presentation, median (IQR)
   Antibiotic use prior to enrollment visit, n (%)

1295 (27)
5 (3–10)
733 (57)
6 (4–7)
561 (43)

20 (15–25)
942 (59)
4 (3–7)

6 (3–13)
1286 (58)
6 (4–10)

8705 (25)

8 (4–19)
4982 (57)
5 (3–7)

390 (24)

1292 (58)

3333 (38)

1595 (>99)

2206 (99)

8669 (>99)

455 (29)

1054 (48)

2804 (32)

19 (14–24)
238 (52)
5 (4–8)
141 (31)

6 (3–13)
618 (59)
8 (5–13)
689 (65)

7 (3–16)
1589 (57)
6 (4–9)
1391 (50)

   Duration of hospital admission in days, median (IQR)

6 (5–9)

6 (4–8)

3 (2–5)

5 (3–7)

   S. Typhi infection, median (IQR)

7 (5–9)

6 (4–8)

3 (2–5)

5 (3–7)

   S. Paratyphi A infection, median (IQR)

6 (5–8)

4 (4–6)

3 (2–3)

Participated in follow-up interview, n (% of culture-confirmed cases)

4562 (94)

1498 (94)

2029 (91)

   Additional symptoms reported, n (%)

346 (8)

265 (18)

105 (5)

    Sought additional medical care, n (%)

251 (73)

135 (51)

N = 34 748.
Abbreviation: IQR, interquartile range.
a

Salmonella Typhi and Paratyphi A.

b

Not including laboratory network facilities.
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69 (66)

5 (3–7)
8089 (93)
716 (9)
455 (64)
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chi-square test and used the Wilcoxon rank-sum test for assessing the differences in the median values of continuous
variables.
Country-specific univariable and multivariable logistic regression models were used to identify potential predictors of
hospitalization among cases identified from the SEAP sites,
including age, gender, serovar (S. Typhi or S. Paratyphi A),
fluoroquinolone resistance, third-generation cephalosporin resistance, prior antibiotic use, and time in days from fever onset
to hospital presentation. Odds ratios (ORs) and 95% confidence
intervals (CIs) were estimated from the models.
Similarly, country-specific univariable and multivariable
negative binomial regression models were used to identify predictors of the duration of hospital stay among patients hospitalized at the SEAP hospitals, including the same predictors
stated above and empiric treatment at hospital presentation.
Relative risks and 95% CIs were estimated from the models. For
all analyses, a P value less than .05 was considered statistically
significant.

Table 3. Characteristics of Patients With Blood Culture–Confirmed Enteric Fever (Salmonella Typhi and Paratyphi A) Enrolled in the Surveillance for
Enteric Fever in Asia Project (SEAP) With Clinical Complications Documented in the Medical Records—Bangladesh, Nepal, and Pakistan, 2016–2019
Patients with Complications, by Country
Pakistan
(n = 60)

All Countries

Bangladesh
(n = 18)

Nepal
(n = 12)

With Complications
(n = 90)

Age, median (IQR), years

5 (3–8)

19 (14–25)

Male gender, n (%)

8 (44)

8 (67)

36 (60)

52 (58)

S. Typhi serovar, n (%)

17 (94)

12 (100)

58 (97)

Fluoroquinolone resistance, n (%)

18 (100)

8 (67)

60 (100)

S. Typhi third-generation cephalosporin
resistance,a n (%)

46 (79)

0 (0)

0 (0)

Without Complications
(n = 5115)

P

Demographics
9 (3–17)

9 (4–17)

6 (3–10)

<.001

2880 (56)

.78

87 (97)

4516 (88)

.01

86 (96)

4902 (96)

.82

46 (79)

932 (63)

.01

Isolate characteristics

Time from fever onset to hospital presentation,
median (IQR), days

6 (3–8)

5 (3–8)

10 (7–16)

Prior antibiotic use,b n (%)

8 (44)

8 (67)

53 (88)

8 (5–14)
69 (77)

5 (3–7)
2679 (52)

<.001
<.001

N = 5205.
Abbreviation: IQR, interquartile range.
a
Pakistan only, where antibiotic resistance testing results were available: n = 58 with complication, n = 1470 without complications; no third-generation cephalosporin resistance was detected in Bangladesh or Nepal.
b

Patient or caregiver reported.

obstruction (n = 6), renal impairment (n = 1), and myocarditis
(n = 1). Intestinal obstructions were secondary complications
only among patients who experienced an intestinal perforation.
Patients infected with S. Typhi who reportedly consumed antibiotics before hospitalization and those who took a longer time
to seek care were more likely to be diagnosed with a complication (Table 3).
Six-Week Follow-up

Of the 8705 confirmed cases, 3 died during hospitalization. Of
the remaining 8702 patients, 8092 (93%) patients or patient
caregivers participated in the follow-up interview at 6 weeks:
Bangladesh, 94% (4562/4873); Nepal, 94% (1498/1602); and
Pakistan, 91% (2029/2230). Study teams were unable to interview 610 (7%) patients; 9 refused to participate and the others
could not be reached. In Pakistan, 64% of patients with typhoid
with known outcomes were infected with strains resistant to
third-generation cephalosporins, as were 71% of those lost to
follow-up and 100% of the fatal cases (Table 4).
A total of 9% (716/8092) of participants contacted reported
symptoms following the enrollment visit; 64% (455/716) sought
additional medical care (Table 2), and 69% (313/455) of those
patients had medical records available for review. One patient
was diagnosed with an intestinal perforation 1 day following
the hospital outpatient visit, an 18-year-old male from Pakistan
with XDR typhoid.
Case-fatality Ratio

Of the 8095 participants with known outcomes (including the
3 who died during hospitalization), we identified 6 deaths, all
culture-positive for S. Typhi (overall case-fatality ratio of .07%;

95% CI, .01–.13%). Two fatal cases occurred in Nepal, both
adult males (33 and 65 years old) who presented to laboratory
network sites and reportedly died after hospital discharge. Four
fatal cases occurred in Pakistan, 2 male and 2 female patients
(8 months–8 years old). Three of these patients died at the
SEAP hospitals during hospitalization and 1 died after the enrollment visit. No deaths were identified in Bangladesh. None of
the fatal cases included a diagnosis of intestinal perforations. In
Pakistan, 3 patients who died reportedly consumed antibiotics
prior to enrollment. All isolates from fatal cases were resistant
to fluoroquinolones, and those in Pakistan were all XDR.
Hospitalization data were available for 8062 of 8095 patients
with known outcomes. Five of the 2605 hospitalized patients
died (case-fatality ratio of .19%; 95% CI, .02–.36%). One patient enrolled as an outpatient (1/5457) died (case-fatality ratio
of .02%; 95% CI, 0–.5%).
Hospitalization

Of the 8669 patients with confirmed enteric fever with available
hospitalization data, 2804 (32%) were hospitalized. Overall,
2576 (92%) of the hospitalized patients with confirmed enteric
fever were infected with S. Typhi (Bangladesh, 89% [1155/1295];
Nepal, 89% [404/455]; Pakistan, 96% [1017/1054]). Among patients infected with S. Typhi, the highest proportion of hospitalizations occurred among children younger than 2 years old
in Bangladesh and Nepal and among those 16 years or older in
Pakistan. Across countries, the highest proportion of hospitalizations among those with S. Paratyphi A infection was among
children younger than 5 years old (Figure 1).
Infection with S. Typhi, reported prior antibiotic use, and
delayed care-seeking were significant common predictors of
Severity and Outcomes of Enteric Fever • cid 2020:71 (Suppl 3) • S225
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Severity

Table 4. Characteristics of Patients With Blood Culture–Confirmed Enteric Fever (Salmonella Typhi and Paratyphi A) Enrolled in the Surveillance for
Enteric Fever in Asia Project (SEAP) by Outcome 6 Weeks Following Enrollment—Bangladesh, Nepal, and Pakistan, 2016–2019
Known Outcomea (n = 8089)

Lost to Follow-up (n = 610)

Died (n = 6)

Demographics
Age, median (IQR), years
Male gender, n (%)

8 (4–19)
4622 (57)

6 (3–12)
356 (58)

6 (2–33)
4 (67)

Isolate characteristics
S. Typhi serovar, n (%)
Fluoroquinolone resistance,b n/N (%)

7037 (87)

548 (90)

6 (100)

7630/7990 (95)

561/602 (93)

6 (100)

S. Typhi third-generation cephalosporin resistance,b n/N (%)
  Bangladesh

0/3797 (0)

0/268 (0)

0/0 (0)

  Nepal

0/1268 (0)

0/80 (0)

0/2 (0)

1223/1900 (64)

136/192 (71)

4/4 (100)

Severity
Time from fever onset to hospital presentation,c median (IQR), days
Prior antibiotic use,d n/N (%)
Hospitalized, n (%)
   Duration of hospital stay,e median (IQR), days
  Complications,e n (%)

5 (3–7)

5 (3–7)

3077 (38)

253 (41)

2600/8056 (32)

199/607 (33)

5 (3–7)
81/4732 (1.7)

6 (3–8)
8/469 (1.7)

8 (4–14)
3 (50)
5 (83)
7 (5–9)
1 (17)

N = 8705.
Abbreviation: IQR, interquartile range.
a

Does not include the 6 patients who died.

b

Patients with antimicrobial resistance testing results available.

c

Includes patients from SEAP hospitals only (not laboratory network sites).

d

Patient or caregiver reported.

e

Among patients with medical charts available for review.

hospitalization across countries in the univariable models. In
the multivariable models, there was a consistent trend in the
direction of the effect for Typhi infection and prior antibiotic
use, which was statistically significant in 2 of the 3 countries.
Resistance to fluoroquinolones and third-generation cephalosporins was associated with higher odds of hospitalization in
Pakistan (Table 5).
Data on duration of hospital stay were available for
96% (1911/1981) of patients admitted to SEAP hospitals
(Bangladesh, 939/940; Nepal, 150/150; Pakistan 822/891). The
median duration of hospital stay was the same for patients with
Typhi and Paratyphi A, 5 days (interquartile range, 3–7 days)
(Table 2). There were no common predictors for duration of
hospital stay across countries. Third-generation cephalosporin
resistance was associated with 48–54% longer hospital stays in
Pakistan (Table 6).
DISCUSSION

The SEAP study generated comprehensive data on illness severity and outcomes among a large cohort of blood culture–
confirmed cases of enteric fever from high-burden settings in
Bangladesh, Nepal, and Pakistan. These data are important for
understanding the burden of severe typhoid, and the burden
that enteric fever places on the healthcare system. This is particularly relevant in settings like South Asia where many severely
ill patients are refused admission due to hospital capacity limitations [15].
S226 • cid 2020:71 (Suppl 3) • Longley et al

Mortality is a critical measure of disease severity and is the
main driver of typhoid disease burden estimates. A recent metaanalysis estimated the overall case fatality of enteric fever to be
2.49% [9]. While this is markedly higher than the case-fatality
ratio identified from SEAP, several of the studies included in
the meta-analysis with higher case-fatality rates utilized small
sample sizes or included studies from as early as 1960. The
2017 Global Burden of Disease Study estimated an overall casefatality rate of 0.95%, with the South Asia–specific estimates
closer to 1.1% [2]. The widely invoked case-fatality ratio of 1%
was estimated using published data from hospital-based studies
and separate community-based studies [10]. Because enteric
fever is generally treated as an outpatient disease, estimates
derived from inpatient surveillance exclude mild cases not admitted to the hospital and may overestimate the case-fatality
ratio [16–19]. However, active surveillance at the community
level detects and treats disease early, providing very limited information on uncommon outcomes like severe complications
and death [16, 20]. We observed such variation in mortality in
the SEAP data, in which the case-fatality ratio among inpatients
was almost 10 times higher than that of outpatients.
Alternatives to the tertiary hospitals in the SEAP settings
are laboratory network sites, data from which are often not included in hospital-based surveillance. These facilities include
community-based private consultation centers, clinics, and
secondary hospitals, and constitute an important component
of a comprehensive enteric fever surveillance system [19]. By

Downloaded from https://academic.oup.com/cid/article/71/Supplement_3/S222/6013556 by guest on 26 January 2021

  Pakistan

100%
90%

70%
60%
50%
40%
30%
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≥16 Overall

<2

Bangladesh

2-4

5-15

≥16 Overall

Nepal

<2

2-4

5-15

≥16 Overall

Pakistan

Age in Years
S. Typhi

S. Paratyphi A

Figure 1. Proportion of Salmonella Typhi and Salmonella Paratyphi A case-patients enrolled in SEAP who were hospitalized by age in years and by country—Bangladesh,
Nepal, and Pakistan, September 2016–September 2019 (S. Typhi, n = 7564; S. Paratyphi A, n = 1105). Abbreviation: SEAP, Surveillance for Enteric Fever in Asia Project.

including laboratory network sites alongside our hospital-based
surveillance, we were able to more accurately estimate the casefatality ratio compared with utilizing tertiary hospitals alone.
While our overall case-fatality ratio of less than 1% is considerably lower than published estimates, it is comparable to recent
findings from Dhaka, Bangladesh, that utilized a similar methodology as SEAP and included patients diagnosed through laboratory network sites [20, 21].
Previous studies have reported higher mortality among patients infected with multidrug-resistant S. Typhi [7–9]. With
improved clinical services and the use of effective antibiotics,
case fatality among blood culture–confirmed enteric fever has
reportedly decreased in recent decades [8, 20, 21]. However,
with widespread antimicrobial resistance, there is a risk of increased severe outcomes. While we did not detect any cephalosporin resistance in Bangladesh or Nepal [22], a recent
molecular surveillance study projected that resistance will
develop in the region because there are documented cases in
Pakistan and India [12, 23]. All deaths from our population
were among patients infected with drug-resistant S. Typhi, including XDR typhoid among all deaths in Pakistan, highlighting

the threat that antimicrobial resistance poses to the currently
low case-fatality ratio.
Similarly, clinical complications attributed to enteric fever
by treating physicians were infrequently identified among
SEAP patients. Hepatitis, septic shock, and pulmonary complications—the complications we commonly identified—are
well documented in the literature [8]. Like the fatal cases, most
patients with a complication were infected with organisms
resistant to antibiotics commonly prescribed in the region.
A study from Vietnam reported complications among an estimated 15% of patients with typhoid and found that clinical complications were associated with intermediate fluoroquinolone
resistance during a time when these drugs were widely used to
treat enteric fever [24]. Because we observed that patients with
third-generation cephalosporin resistance were more likely to
develop a typhoid-related complication, we anticipate the rates
of severe disease to increase as this class of antimicrobials, including ceftriaxone and cefixime, is commonly prescribed empirically in the SEAP settings [25].
A considerable proportion of blood culture–confirmed enteric fever cases were hospitalized across the 3 countries,
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Proportion Hospitalized

80%

Table 5. Univariable and Multivariable Analysis of Factors Associated With Hospitalization Among Patients With Blood Culture–Confirmed Enteric Fever
(Salmonella Typhi and Paratyphi A) Enrolled in the Surveillance for Enteric Fever in Asia Project (SEAP), by Country—Bangladesh, Nepal, and Pakistan,
September 2016–September 2019
Bangladesh

Nepal
a

Pakistan
a

Multivariablea
(n = 1548)

Univariable
(n = 4868)

Multivariable
(n = 3003)

<2

2.82 (2.21, 3.60)*

5.51 (1.90, 16.01)*

1.74 (.67, 4.53)

3.19 (.41, 24.96)

.83 (.62, 1.11)

.70 (.48, 1.03)

2–4

2.17 (1.80, 2.64)*

3.87 (1.35, 11.10)*

.76 (.37, 1.55)

2.31 (.75, 7.15)

.92 (.72, 1.17)

.73 (.53, 1.02)

5–15

1.61 (1.34, 1.93)*

3.10 (1.08, 8.90)*

1.47 (1.14, 1.89)*

3.10 (2.01, 4.80)*

1.00 (.80, 1.26)

.99 (.73, 1.33)

≥16

Ref

Ref

Ref

Ref

Univariable
(n = 1595)

Multivariable
(n = 519)

Univariable
(n = 2206

Age in years

Ref

Ref

Female
Male

Ref
1.00 (.88, 1.14)

Ref
.91 (.78, 1.07)

Ref
.70 (.55, .86)*

Ref
.78 (.51, 1.28)

Ref
1.09 (.92, 1.29)

Ref
1.16 (.93, 1.45)

Species
S. Paratyphi A
S. Typhi

Ref
1.67 (1.37, 2.03)*

Ref
1.43 (1.10, 1.84)*

Ref
1.51 (1.09, 2.11)*

Ref
1.58 (.91, 2.74)

Ref

Ref

2.41 (1.63, 3.56)*

1.70 (1.05, 2.74)*

Fluoroquinolone sensitivity
Susceptible
Reduced susceptibility

Ref
1.57 (.93, 2.63)

Ref
2.64 (1.27, 5.48)*

Ref
.88 (.64, 1.22)

Ref
.84 (.45, 1.59)

Ref

Ref

2.84 (1.81, 4.47)*

1.98 (1.18, 3.32)*

Third-generation cephalosporin
sensitivityb
Susceptible

Ref

Ref

Ref

Ref

Ref

Ref

Resistant

…

…

…

…

2.07 (1.74, 2.47)*

1.78 (1.40, 2.27)*

Prior antibiotic use
No

Ref

Yes

1.75 (1.53, 1.99)*

Ref
1.32 (1.12, 1.56)*

Ref
1.62 (1.27, 2.07)*

Ref
1.33 (.61, 2.00)

Ref

Ref

1.78 (1.50, 2.11)*

2.05 (1.62, 2.58)*

Days from fever onset to hospital
presentationc
<3 days

Ref

Ref

Ref

Ref

Ref

Ref

3–5 days

1.14 (.87, 1.49)

1.11 (.85, 1.46)

1.17 (.67, 2.06)

1.10 (.61, 2.00)

.68 (.42, 1.07)

.61 (.38, .99)*

6–9 days

2.04 (1.55, 2.69)*

1.87 (1.40, 2.47)*

2.86 (1.56, 5.25)*

2.53 (1.32, 4.85)*

1.53 (.97, 2.43)

1.17 (.72, 1.90)

≥10 days

2.70 (1.89, 3.87)*

2.55 (1.76, 3.69)*

2.46 (1.21, 5.01)*

2.31 (1.08, 4.92)*

3.67 (2.27, 5.93)*

2.47 (1.50, 4.14)*

Data are presented as ORs (95% CI). *P < .05.
Abbreviations: CI, confidence interval; OR, odds ratio; Ref, reference.
a

Multivariable models include patients recruited from SEAP hospitals only.

b

Cephalosporin resistance only detected in Pakistan.

c

For SEAP hospital patients only; data not available for laboratory network patients.

especially among children who would benefit from typhoid
conjugate vaccines (TCVs), which are safe for children as young
as 6 months old [26]. Similar to our findings from SEAP, a surveillance study for enteric fever in Bangladesh identified that
almost 41% of patients with blood culture–confirmed enteric
fever younger than 2 years old were hospitalized [21]. With the
introduction of TCVs into routine immunization and improved
access to safe water, food, and sanitation and hygiene facilities,
we expect a reduction in typhoid hospitalizations, making hospital beds available for patients requiring inpatient care for
other conditions [15].
Antibiotics are widely available without prescription in the
communities under SEAP surveillance. We observed that hospitalization was associated with antimicrobial use and resistance,
especially in Pakistan, which is currently experiencing an ongoing outbreak of XDR typhoid [12]. Delayed care-seeking and
self-reported prior antibiotic use, while only moderately reliable
S228 • cid 2020:71 (Suppl 3) • Longley et al

[27], were also associated with higher odds of severe disease,
consistent with previous findings [8, 28]. Reasons for delayed
care-seeking are unknown; possibly some patients presented to
the study sites only after treatment failure, especially in cases of
drug resistance [29]. Empiric treatment was also common in
our sites [25]. Such treatment, in addition to indiscriminate antibiotic usage in settings already detecting drug-resistant enteric
fever, may put patients at risk for poor outcomes due to delays
in appropriate therapy [4, 11, 30]. Indeed, empiric treatment in
Pakistan was associated with a longer duration of hospital stay,
most probably due to ineffective initial treatment. Similarly, patients from Pakistan with evidence of XDR typhoid were admitted for approximately 50% longer than those with non-XDR
typhoid. The longer duration of hospital stay may be attributed
to morbidity but may also be driven by the need for intravenous
carbapenem therapy. Typhoid vaccination could potentially reduce the overprescribing of antibiotics, the subsequent spread
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Gender

Table 6. Univariable and Multivariable Analysis of Factors Associated With Duration of Hospital Stay Among Hospitalized Patients With Blood Culture–
Confirmed Enteric Fever (Salmonella Typhi and Paratyphi A) Enrolled in the Surveillance for Enteric Fever in Asia Project (SEAP), by Country—Bangladesh,
Nepal, and Pakistan, September 2016–September 2019
Bangladesh

Nepal
Univariable
(n = 150)

Pakistan

Univariable
(n = 939)

Multivariable
(n = 927)

Multivariable
(n = 149)

Univariable
(n = 822)

Multivariable
(n = 790)

<2

1.00 (.63, 1.58)

1.00 (.63, 1.58)

1.47 (.94, 2.31)

1.61 (.95, 2.73)

.99 (.84, 1.17)

.96 (.82, 1.12)

2–4

.97 (.62, 1.53)

.98 (.62 1.55)

1.52 (1.08, 2.16)*

1.53 (1.09, 2.15)*

1.10 (.97, 1.25)

1.04 (.92, 1.18)

5–10

1.06 (.67, 1.67)

1.06 (.67, 1.67)

1.46 (1.27, 1.68)*

1.46 (1.27, 1.68)*

1.05 (.94, 1.80)

1.05 (.94, 1.17)

≥16

Ref

Ref

Age in years

Ref

Ref

Ref

Ref

Female
Male

Ref

Ref

1.01 (.95, 1.07)

1.01 (.95, 1.07)

Ref
.97 (.84, 1.13)

Ref
.91 (.79, 1.04)

Ref
1.03 (.94, 1.13)

Ref
1.10 (1.00, 1.20)*

Serovar
S. Paratyphi A
S. Typhi

Ref

Ref

1.08 (.98, 1.20)

1.08 (.97, 1.19)

Ref
1.30 (1.04, 1.63)*

Ref
1.27 (1.03, 1.57)*

Ref
1.09 (.87, 1.37)

Ref
1.02 (.79, 1.33)

Fluoroquinolone sensitivity
Susceptible

Ref

Ref

.77 (.58, 1.01)

.76 (.57, 1.00a)*

Susceptible

Ref

Ref

Ref

Ref

Resistant

…

…

…

…

Reduced susceptibility

Ref
.85 (.69, 1.05)

Ref
.86 (.71, 1.04)

Ref
1.26 (.93, 1.69)

Ref
1.00 (.75, 1.34)

Third-generation cephalosporin
sensitivityb
Ref
1.48 (1.34, 1.64)*

Ref
1.54 (1.39, 1.72)*

Prior antibiotic use
No

Ref

Ref

Yes

1.01 (.95, 1.07)

1.01 (.95, 1.07)

Ref
1.08 (.93, 1.25)

Ref
1.12 (.97, 1.29)

Ref
.98 (.88, 1.08)

Ref
1.06 (.95, 1.18)

Empirically treated
No

Ref

Yes

.99 (.92, 1.06)

Ref
.99 (.92, 1.06)

Ref
.89 (.74, 1.06)

Ref
1.02 (.86, 1.20)

Ref
1.27 (1.15, 1.42)*

Ref
1.22 (1.10, 1.35)*

Days from fever onset to hospital
presentation
<3 days

Ref

Ref

Ref

Ref

Ref

Ref

3–5 days

.97 (.87, 1.08)

.97 (.87, 1.09)

.85 (.68, 1.07)

.77 (.62, .96)*

1.06 (.84, 1.33)

.99 (.79, 1.24)

6–9 days

.98 (.88, 1.09)

.98 (.87, 1.09)

.94 (.75, 1.18)

.83 (.66, 1.03)

.94 (.75, 1.18)

.86 (.69, 1.08)

≥10 days

.91 (.79, 1.03)

.89 (.77, 1.02)

.89 (.68, 1.17)

.79 (.62, 1.02)

.96 (.77, 1.21)

.85 (.68, 1.07)

Data are presented as RRs (95% CI). *P < .05.
Abbreviations: CI, confidence interval; Ref, reference; RR, relative risk.
a

Rounding: .76 (.57, .9985); P = .0488.

b

Cephalosporin resistance only detected in Pakistan.

of antimicrobial resistance [26], and the overall burden on the
healthcare system.
An important limitation to our study is the potential to miss
the most severe cases of enteric fever. To ascertain complications, data were abstracted from medical records of blood culture–confirmed patients who sought care at the SEAP hospitals.
However, most patients with enteric fever likely seek care at
pharmacies or informal care systems and never present to hospitals [31]. We may have missed severe disease and enteric fever
deaths among those who did not present to a hospital or who
did not obtain diagnostic tests, as these are costly and not always required before treatment [15, 16]. Nevertheless, we were
able to review over 5000 medical records of blood culture–confirmed cases. We may have missed deaths among patients lost

to follow up, especially patients in Pakistan with XDR typhoid
infections who would be more likely to have severe outcomes,
including death. While our loss to follow-up was low, our estimated case-fatality ratio is likely biased downwards. Because
it may be more difficult to contact families of individuals who
died, those reached for follow-up may not be representative of
the true case-fatality ratio. However, our hospitalization estimates—an important measure of severity—may be overestimated because we calculated the proportion hospitalized only
among those patients with enteric fever presenting to a hospital or laboratory network site, which does not consider the
large proportion of cases who seek care at pharmacies or other
clinics, especially those with mild disease. Last, blood culture
sensitivity is estimated to be approximately 60%—or lower for
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those with prior antibiotic use [32]. Therefore, we likely missed
additional enteric fever cases presenting to our study sites who
were not confirmed by blood culture, including patients with
enteric fever–related intestinal perforations [33]. Future surveillance should prioritize reducing the loss to follow-up of
blood culture–confirmed cases to improve the accuracy of case
fatality and severe disease estimates.
Conclusions
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While clinical complications and deaths were rarely identified in
our large dataset, the high proportion of hospitalizations and prolonged hospital stays, reflecting substantial costs and morbidity,
underscores the benefit of immediate interventions. Case fatality
from enteric fever is not a static figure; it varies according to
context and time. We found a lower-than-expected case-fatality
ratio but noted that extensive drug resistance is associated with
more severe disease and morality, and global data demonstrate a
continuing trend in the emergence and spread of drug-resistant
strains. Thus, continuing to monitor enteric fever mortality is
important and can be added to existing hybrid surveillance at
a low marginal cost. The World Health Organization’s Strategic
Advisory Group of Experts (SAGE) on Immunization has recommended TCV introduction in countries with a high burden
of typhoid fever or with a high burden of antimicrobial-resistant
S. Typhi, both scenarios applicable at the SEAP sites [34]. Patient
outcomes, disease severity, and the impact of antimicrobial resistance should drive decision making on enteric fever interventions, including vaccine deployment. With support from
Gavi, the Vaccine Alliance to introduce TCVs, more countries
will need reliable burden data for vaccine implementation. It is
also important to note that there is an identified burden of S.
Paratyphi A, which is not covered by the current vaccines, further emphasizing the need to monitor trends in disease burden
and severity among patients with enteric fever.
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